Secukinumab Provides Clinical Benefit for JIA Subtypes Secukinumab Provides Clinical Benefit for JIA Subtypes

Phase 3 trial shows secukinumab is effective for enthesitis-related arthritis and juvenile psoriatic arthritis in children.Medscape Medical News

Source: Medscape Pharmacist Headlines - June 16, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news